Skip to main content
Medical information Clinical review pending

Genetic Testing

MYO1E Gene Focal Segmental Glomerulosclerosis Type 6 Genetic Test

Genetic test to identify mutations in the MYO1E gene associated with Focal Segmental Glomerulosclerosis (FSGS), a kidney disorder. Helps in early diagnosis and management.

General information only: This page is not a diagnosis or personal medical advice. A qualified clinician should decide whether testing is appropriate and interpret results in context.

Review status: No completed medical review is recorded for this page.

Ask a question
Counselor guidance included Confidential handling Kenya-wide coordination

At a glance

Plan your test

Sample
Blood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
Results
Confirm with the laboratory before booking.
Preparation
Confirm with the laboratory before booking. A clinical history and genetic counseling session, including pedigree chart creation, are recommended prior to testing.
Test priceKSh 40,000

Payment: M-Pesa and card options can be confirmed during booking.

Insurance & government schemes

Is this test covered for you?

We help you verify whether the MYO1E Gene Focal Segmental Glomerulosclerosis Type 6 Genetic Test test can be claimed against your insurer, employer scheme or a Kenyan government health scheme — before you book. Coverage depends on your plan, clinical indication and your provider's rules; final approval always rests with them.

Talk to a claims advisor

Providers & schemes we can help you check

Government & public schemes

SHIF — Social Health Insurance Fund Linda Mama EduAfya NHIF (legacy cards)

Eligibility and benefits follow the current rules of the Social Health Authority (SHA) and applicable government programmes.

Private insurers & employer schemes

Jubilee Health AAR APA Britam CIC Madison Resolution Pioneer Minet Old Mutual GA Life Heritage + other licensed insurers

Names shown for identification only — listing does not imply partnership or guarantee of coverage.

Have these ready when we check

  • Insurer or scheme name & policy / member number
  • A clinician's request / prescription for the test
  • Pre-authorisation letter, if your plan requires one

Free coverage check

Ask us to verify your cover

Send your details and our claims team confirms what documents you need and whether pre-authorisation applies — usually the same working day.

+254

Used only to process your coverage check — see our Privacy Policy. Verification support is free and does not guarantee your provider will pay.

01

Start with fit

Is this the right test for you?

The best test starts with a clear clinical question. These are common reasons a clinician or family may consider this test.

  • ✓Suspected diagnosis of FSGS Type 6.
  • ✓Family history of FSGS or related kidney diseases.
  • ✓Unexplained kidney dysfunction.
  • ✓Proteinuria.
  • ✓Edema.
  • ✓Hypertension associated with kidney issues.
02

In plain language

What this test helps you understand

Identifies mutations in the MYO1E gene associated with Focal Segmental Glomerulosclerosis (FSGS) Type 6, aiding in diagnosis and management of this kidney disorder.
The MYO1E Gene Focal Segmental Glomerulosclerosis Type 6 NGS Genetic DNA Test is a specialized genetic analysis designed to detect mutations within the MYO1E gene. Mutations in this gene are linked to a specific type of kidney disease called Focal Segmental Glomerulosclerosis (FSGS). FSGS can lead to significant kidney damage and complications if not identified and managed promptly. Understanding your genetic risk related to the MYO1E gene can provide valuable information for healthcare decisions.

This test examines your genetic material, typically obtained from a blood sample or extracted DNA, to identify specific changes in the MYO1E gene. Detecting these mutations can help confirm a genetic predisposition to FSGS.

Individuals with a personal or family history of kidney disease, or those presenting with symptoms like unexplained kidney problems, protein in the urine, swelling, or high blood pressure, may be candidates for this test. Early detection allows for proactive management and potentially better health outcomes.

Benefits of this test include the potential for early diagnosis of a genetic kidney condition, informing treatment strategies, facilitating genetic counseling for family members, and enabling personalized kidney health management.

Results will indicate the presence or absence of specific MYO1E gene mutations. Interpretation of results and discussion of implications should be done with a qualified healthcare professional or genetic counselor.
03

Medical review status

Clinical review pending

A completed medical review is not recorded for this page. No clinician has endorsed the information shown here. Please discuss testing decisions with a qualified healthcare professional.

Meet the DNA Labs Kenya medical team →
04

A simple process

What happens next?

You do not have to navigate the test alone. We help you move from question to next step.

1

Speak with us

We check the test and answer your questions before collection.

2

Give your sample

Choose home collection or a coordinated hub visit in Kenya. We explain whether this test uses a cheek swab or blood draw.

3

Understand your report

A counselor helps you understand the result and the next steps.

05

Choose your collection

Home collection or a lab visit

We will explain the sample, preparation, and next steps before anything is collected.

Home collection

Choose a coordinated visit at home or another convenient location. Our team confirms the appointment and sample requirements in advance.

Lab or hub visit

Prefer to visit a coordinated location? We can guide you to the right hub and explain what to expect when you arrive.

Ask about locations →
PreparationConfirm with the laboratory before booking. A clinical history and genetic counseling session, including pedigree chart creation, are recommended prior to testing.
SampleBlood sample (EDTA tube), extracted DNA, or one drop of blood on an FTA card.
MethodologyNext-Generation Sequencing (NGS) analysis of the MYO1E gene.
PrivacyYour sample and report are handled confidentially. Ask the team how your information is stored and shared.
This test specifically targets mutations in the MYO1E gene. It does not detect mutations in other genes associated with FSGS or other kidney diseases. A negative result does not completely rule out a genetic cause for kidney disease. Confirm with the laboratory before booking.
06

Read your report

What common result terms mean

PositiveA finding was identified. Your clinician or counselor will explain what it means for your care.
NegativeThe specific finding tested for was not identified. It does not rule out every possible cause.
VUSA variant was found, but current evidence is not enough to classify it. Your counselor can explain follow-up.
07

Questions people ask

Frequently asked questions

Focal Segmental Glomerulosclerosis (FSGS) is a disease that affects the glomeruli, the tiny filtering units in the kidneys. It can lead to kidney damage and failure.
The MYO1E gene provides instructions for making a protein important for the function of certain cells, including those in the kidneys.
Individuals with symptoms of kidney disease, a family history of FSGS, or unexplained kidney problems may be recommended for this test by their doctor.
Results indicate if specific mutations in the MYO1E gene are found. A healthcare professional or genetic counselor will help explain the results and their implications.
Yes, genetic counseling before and after testing is highly recommended to understand the test, its implications, and potential results.
Your doctor will discuss the results with you and recommend appropriate management or treatment strategies based on your specific situation.
08

Collaboration

Open for partnership with hospitals, clinics, doctors & researchers

Whether you are referring patients, building a research programme or supporting students, we work as an extension of your team — with responsive communication and clear scientific standards.

Hospitals & clinics

Referral pathways, coordinated sample logistics and shared reporting that fits your clinical workflow.

Doctors & specialists

LOINC-coded reports, ACMG-based variant classification and a direct scientific line for complex cases.

Research institutions

Sanger sequencing, NGS panels and custom assays — with project design support, batch pricing and agreed turnaround commitments.

Students & academic projects

Discounted laboratory services for college, master's and PhD research projects — including proposal guidance and cost-effective batch testing.

Explore partnerships
09

Trust & transparency

Sources, standards & how this page is maintained

Standards & references

  • ACMG/AMP technical standards for sequence variant interpretation
  • ClinGen curation and gene–disease validity frameworks where applicable
  • LOINC-coded reporting for interoperable results
  • ISO 9001:2015 quality management; ISO 15189 accreditation in progress

Page provenance

  • Last updated: September 27, 2026
  • Medical review: not yet completed
  • Written for patients & clinicians in Kenya; reviewed periodically against current guidance

Medical disclaimer: this page is general information, not a diagnosis or personal medical advice. Testing decisions and result interpretation should be made with a qualified healthcare professional.

Keep exploring

Related tests

View all tests →
Chat on WhatsApp